Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectrum Pharmaceuticals Inc.

www.sppirx.com/

Latest From Spectrum Pharmaceuticals Inc.

Hanmi In Tough Spot After Sanofi Efpeglenatide U-Turn

Sanofi’s decision to return to originator Hanmi all rights to the novel diabetes candidate efpeglenatide, which is in global Phase III trials, has placed the South Korean pharma in a difficult spot. Unless there are some surprisingly positive data, finding a major global partner for commercialization may be tough.

South Korea Deals

Novartis’s Capmatinib Shows High Response Rates In NSCLC

The MET inhibitor already pending US FDA approval had good results in patients with brain metastases. Spectrum’s TKI inhibitor poziotinib continues to be studied after Cohort 1 failure.

Clinical Trials Cancer

Spectrum Sinks After Poziotinib Fail In NSCLC

The US firm has two assets but the future looks less than rosy for one of them, the lung cancer therapy poziotinib, after the drug failed a Phase II study.

Clinical Trials Cancer

Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Alias(es)
  • NeoTherapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Spectrum Pharmaceuticals Inc.
  • Senior Management
  • Joseph W Turgeon, Pres. & CEO
    Kurt Gustafson, EVP, CFO & Principal Accounting Officer
    Thomas Riga, COO
    Bimal R Shah, VP, Corp. & Bus. Dev.
    Francois Lebel, MD, CMO
  • Contact Info
  • Spectrum Pharmaceuticals Inc.
    Phone: (702) 835-6300
    11500 South Eastern Ave.
    Ste. 240
    P.O. Box 5702 Henderson, NV 89052
    USA
UsernamePublicRestriction

Register